# A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

> **NCT05653219** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 152 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

- **BIOLOGICAL:** Ianalumab
- **DRUG:** Eltrombopag
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05653219
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-02
- **Primary completion:** 2025-06-19
- **Final completion:** 2028-04-08
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653219, "A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05653219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*